Although recommendations regarding germline incidental findings exist, they are not specific for tumor testing. Clinical oncology panels have become larger and it is anticipated that this trend will continue with the possibility that tumor exomes may routinely be tested in the future. With this increase in the breadth of testing, the detection of germline or potential germline incidental findings is expected to increase. Recommendations regarding incidental findings are somewhat controversial, have changed over time, and were not designed for the setting of routine tumor testing. This webinar will discuss the unique considerations regarding germline incidental findings found during tumor testing, including patient specific issues such as consent and timing of testing; reimbursement and billing issues; and laboratory issues such as reflex testing protocols, workflow processes, bioinformatics processes, and prior precedent in laboratory testing.
- Understand which variants may be considered an incidental finding
- Learn the frequency of incidental findings in tumor testing and the features that affect that frequency
- Become familiar with laboratory issues that arise when evaluating whether and how to report incidental findings in the setting of tumor testing
Sophia Yohe, MD, FCAP